Incorporation of bevacizumab in the primary treatment of ovarian cancer.

By R. Burger, M. Brady, M. Bookman, G. Fleming, B. Monk, Helen Q. Huang, Robert S. Mannel, H. Homesley, J. Fowler, B. Greer and 3 more. New England Journal of Medicine, 2011

2,288 citations recorded by the source corpus.

Subfields: Biotechnology, Molecular Biology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/1bf5dce8d1d8b41e37d08f434c08d3f9f38ea831

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. N. Vasudev
2. A. Adamis
3. N. Ferrara
4. Andrew R Reynolds

In Molecular Biology

1. A. Adamis
2. N. Ferrara
3. N. Vasudev
4. Andrew R Reynolds
5. C. Sessa
6. M. Mirza
7. A. González-Martín
8. Rakesh K. Jain

In Reproductive Medicine

1. C. Sessa
2. M. Mirza
3. A. González-Martín

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “The elucidation of the crystal structure of the VEGFR2 kinase domain 106 enabled the development of other Bevacizumab also significantly increased PFS in a large randomized study in patients with stage III or stage IV ovarian cancer who had undergone debulking surgery (GOG0218) 92 .”
• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Two large randomised clinical trials (GOG-218 and ICON-7) have assessed the addition of bevacizumab to the combination of paclitaxel and carboplatin in front-line therapy [46, 47].”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, methodology): “Paclitaxel/carboplatin ± bevacizumab GOG218 [37] Improvement in PFS, OS confounded by cross-over”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “3 [119]”
• Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer (2019, neutral): “Abdominal pain 118 (32) 14 (4) 113 (30) 13 (3) 127 (34) 17 (5)”